Search

Your search keyword '"Fukagai, Takashi"' showing total 220 results
Start Over Author "Fukagai, Takashi"
220 results on '"Fukagai, Takashi"'

2. Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907)

Author

Yorozu, Atsunori, Namiki, Mikio, Saito, Shiro, Egawa, Shin, Yaegashi, Hiroshi, Konaka, Hiroyuki, Momma, Tetsuo, Fukagai, Takashi, Tanaka, Nobumichi, Ohashi, Toshio, Takahashi, Hiroyuki, Nakagawa, Yoko, Kikuchi, Takashi, Mizokami, Atsushi, and Stone, Nelson N.

Published
2024
Full Text
View/download PDF

3. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer

Author

Nepal, Sat Prasad, Nakasato, Takehiko, Fukagai, Takashi, Ogawa, Yoshio, Nakagami, Yoshihiro, Shichijo, Takeshi, Morita, Jun, Maeda, Yoshiko, Oshinomi, Kazuhiko, Unoki, Tsutomu, Noguchi, Tetsuo, Inoue, Tatsuki, Kato, Ryosuke, Amano, Satoshi, Mizunuma, Moyuru, Kurokawa, Masahiro, Tsunokawa, Yoshiki, and Yasuda, Sou

Published
2023
Full Text
View/download PDF

4. Report of the third Asian Prostate Cancer study meeting

Author

Lojanapiwat, Bannakij, Lee, Ji Youl, Gang, Zhu, Kim, Choung-Soo, Fai, Ng Chi, Hakim, Lukman, Umbas, Rainy, Ong, Teng Aik, Lim, Jasmine, Letran, Jason L, Chiong, Edmund, Lee, Seung Hwan, Türkeri, Levent, Murphy, Declan G, Moretti, Kim, Cooperberg, Matthew, Carlile, Robert, Hinotsu, Shiro, Hirao, Yoshihiko, Kitamura, Tadaichi, Horie, Shigeo, Onozawa, Mizuki, Kitagawa, Yasuhide, Namiki, Mikio, Fukagai, Takashi, Miyazaki, Jun, and Akaza, Hideyuki

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Prostate Cancer, Urologic Diseases, Aging, Asia, Database, Prospective study, Prostate cancer, Registry, Clinical sciences, Oncology and carcinogenesis
Abstract

The Asian Prostate Cancer (A-CaP) study is an Asia-wide initiative that was launched in December 2015 in Tokyo, Japan, with the objective of surveying information about patients who have received a histopathological diagnosis of prostate cancer (PCa) and are undergoing treatment and clarifying distribution of staging, the actual status of treatment choices, and treatment outcomes. The study aims to clarify the clinical situation for PCa in Asia and use the outcomes for the purposes of international comparison. Following the first meeting in Tokyo in December 2015, the second A-CaP meeting was held in Seoul, Korea, in September 2016. This, the third A-CaP meeting, was held on October 14, 2017, in Chiang Mai, Thailand, with the participation of members and collaborators from 12 countries and regions. In the meeting, participating countries and regions presented the current status of data collection, and the A-CaP office presented a preliminary analysis of the registered cases received from each country and region. Participants discussed ongoing challenges relating to data input and collection, institutional, and legislative issues that may present barriers to data sharing, and the outlook for further patient registrations through to the end of the registration period in December 2018. In addition to A-CaP-specific discussions, a series of special lectures were also delivered on the situation for health insurance in the United States, the correlation between insurance coverage and PCa outcomes, and the outlook for robotic surgery in the Asia-Pacific region. Members also confirmed the principles of authorship in collaborative studies, with a view to publishing original articles based on A-CaP data in the future.

Published
2019

5. Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial

Author

Izumi, Kouji, Shima, Takashi, Mita, Koji, Kato, Yuki, Kamiyama, Manabu, Inoue, Shogo, Tanaka, Nobumichi, Hoshi, Seiji, Okamura, Takehiko, Yoshio, Yuko, Enokida, Hideki, Chikazawa, Ippei, Kawai, Noriyasu, Hashimoto, Kohei, Fukagai, Takashi, Shigehara, Kazuyoshi, Takahara, Shizuko, Kadono, Yoshifumi, and Mizokami, Atsushi

Published
2022
Full Text
View/download PDF

6. Clinical questions in the Japanese Urological Association's 2024 clinical practice guidelines for urethral strictures.

Author

Horiguchi, Akio, Shinchi, Masayuki, Hirano, Yusuke, Asanuma, Hiroshi, Ishiura, Yoshiyuki, Inoue, Koji, Kanematsu, Akihiro, Tabei, Tadashi, Tamura, Yoshimi, Nakajima, Yosuke, Moriya, Kimihiko, Yagihashi, Yusuke, Fukagai, Takashi, and Fujii, Yasuhisa

Subjects
URETHRA stricture, DELPHI method, GENERAL practitioners, MEDICAL protocols, URETHROPLASTY, URETHRA diseases
Abstract

Transurethral procedures such as direct vision internal urethrotomy and urethral dilation have been the traditional treatments for urethral strictures. However, transurethral procedures are associated with high recurrence rates, resulting in many uncured cases and prompting major international urological societies to recommend urethroplasty as the standard treatment owing to its high success rate. In contrast, many Japanese general urologists have little doubts about treating urethral strictures with transurethral treatment. Therefore, urethral stricture treatments in Japan are not in line with those used in other countries. To address this, the Trauma, Emergency Medicine, and Reconstruction Subcommittee of the Japanese Urological Association has developed guidelines to offer standardized treatment protocols for urethral stricture, based on international evidence and tailored to Japan's medical landscape. These guidelines target patients with a clinically suspected urethral stricture and are intended for urologists and general practitioners involved in its diagnosis and treatment. Following the Minds Clinical Practice Guideline Development Manual 2020, the committee identified eight critical clinical issues and formulated eight clinical questions using the "patient, intervention, comparison, and outcome" format. A comprehensive literature search was conducted. For six clinical questions addressed by the existing guidelines or systematic reviews, the level of evidence was determined by qualitative systematic reviews. Quantitative systematic reviews and meta‐analyses were performed for the two unique clinical questions. The recommendation grades were determined using the Delphi method and consensus by the committee. These guidelines will be useful to clinicians in daily practice, especially those involved in the care of urethral strictures. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Radiation proctitis after iodine‐125 low‐dose‐rate prostate brachytherapy utilizing SpaceOAR hydrogel.

Author

Morita, Masashi, Hiramatsu, Aya, Nishimura, Kota, Yanagida, Wahei, Nakamura, Saori, Yamatoya, Jin, Noguchi, Tetsuo, Tanabe, Mayo, Fukagai, Takashi, and Lederer, John L.

Subjects
ELECTROCOAGULATION (Medicine), EXTERNAL beam radiotherapy, RADIOISOTOPE brachytherapy, PROSTATE cancer, PROSTATE
Abstract

Objective: We retrospectively evaluated the efficacy of combining the SpaceOAR (SOAR) hydrogel with prostate brachytherapy, using colonoscopy findings to assess for radiation proctitis. Methods: Among 731 patients undergoing iodine‐125 low‐dose‐rate prostate brachytherapy (LDR‐BT), SOAR was utilized in 394 patients (53.9%). Colonoscopy was performed for 97 patients (13.3%) to assess the presence, location, condition, and treatment of radiation proctitis. We also investigated treatment factors associated with the occurrence of radiation proctitis. Results: Radiation proctitis was observed in 57 patients (7.8%) and 17 (2.3%) were treated with argon plasma coagulation (APC). The incidence of radiation proctitis was 12.2% in the non‐SOAR and 4.1% in the SOAR group (p < 0.001). In the non‐SOAR group, the incidence of radiation proctitis was 6.6% for LDR‐BT monotherapy and increased to 22.0% when combined with external beam radiation therapy (EBRT) (p = 0.001). However, in the SOAR group, these rates significantly decreased to 3.3% and 5.7% for monotherapy and combination therapy, respectively (p = 0.035, p < 0.001). With SOAR, inflammation was observed directly above the DL in most patients (87.5%), and only one patient (6.3%) required APC. The absence of SOAR (p < 0.001, HR = 0.29) and the concurrent use of EBRT (p = 0.018, HR = 2.87) were identified as significant risk factors for the occurrence of radiation proctitis. Conclusion: The use of SOAR significantly reduced the incidence of radiation proctitis in patients undergoing LDR‐BT monotherapy and combined EBRT. Inflammation primarily occurred directly above the DL; further examination is necessary to clarify its cause. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa

Author

Mita, Koji, primary, Izumi, Kouji, additional, Goriki, Akihiro, additional, Tasaka, Ryo, additional, Hatayama, Tomoya, additional, Shima, Takashi, additional, Kato, Yuki, additional, Kamiyama, Manabu, additional, Inoue, Shogo, additional, Tanaka, Nobumichi, additional, Hoshi, Seiji, additional, Okamura, Takehiko, additional, Yoshio, Yuko, additional, Enokida, Hideki, additional, Chikazawa, Ippei, additional, Kawai, Noriyasu, additional, Hashimoto, Kohei, additional, Fukagai, Takashi, additional, Shigehara, Kazuyoshi, additional, Takahara, Shizuko, additional, Kadono, Yoshifumi, additional, and Mizokami, Atsushi, additional

Published
2024
Full Text
View/download PDF

12. Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907)

Author

Yorozu, Atsunori, primary, Namiki, Mikio, additional, Saito, Shiro, additional, Egawa, Shin, additional, Yaegashi, Hiroshi, additional, Konaka, Hiroyuki, additional, Momma, Tetsuo, additional, Fukagai, Takashi, additional, Tanaka, Nobumichi, additional, Ohashi, Toshio, additional, Takahashi, Hiroyuki, additional, Nakagawa, Yoko, additional, Kikuchi, Takashi, additional, Mizokami, Atsushi, additional, and Stone, Nelson N., additional

Published
2023
Full Text
View/download PDF

15. Results of a multicenter, randomized, phase 3 trial of trimodality therapy with I-125 brachytherapy, external beam radiation therapy, and long- versus short-term androgen deprivation therapy for localized high-risk prostate cancer (TRIP/TRIGU0907).

Author

Yorozu, Atsunori, primary, Namiki, Mikio, additional, Saito, Shiro, additional, Egawa, Shin, additional, Yaegashi, Hiroshi, additional, Hiroyuki, Konaka, additional, Momma, Tetsuo, additional, Fukagai, Takashi, additional, Tanaka, Nobumichi, additional, Ohashi, Toshio, additional, Takahashi, Hiroyuki, additional, Mizokami, Atsushi, additional, Nakagawa, Yoko, additional, Kikuchi, Takashi, additional, and Stone, Nelson, additional

Published
2023
Full Text
View/download PDF

16. Secondary bladder cancer after permanent iodine-125 brachytherapy for prostate cancer

Author

Hirayama, Kidai, primary, Fukagai, Takashi, additional, Morita, Masashi, additional, Oshinomi, Kazuhiko, additional, Nishimura, Kota, additional, Yamatoya, Jin, additional, Nakagami, Yoshihiro, additional, Toyofuku, Kosuke, additional, Niiya, Akifumi, additional, Kobayashi, Rei, additional, Nishimura, Emi, additional, Kato, Masako, additional, Morota, Madoka, additional, and Ito, Yoshinori, additional

Published
2023
Full Text
View/download PDF

19. Erectile dysfunction in young patients and elderly patients by sexual encounter profile: A comparative study

Author

Yamagishi, Motoki, primary, Ogushi, Yuta, additional, Niikura, Ayana, additional, Ohta, Tomoka, additional, Ichimura, Yuki, additional, Hashimoto, Yu, additional, Kurokawa, Ippei, additional, Sugishita, Hiroo, additional, Tanifuji, Satoru, additional, Imamura, Yuichiro, additional, Shimoyama, Hideaki, additional, Hayashi, Keiichiro, additional, Ishikawa, Kimiyasu, additional, Ohta, Michiya, additional, Sasaki, Haruaki, additional, and Fukagai, Takashi, additional

Published
2022
Full Text
View/download PDF

20. Enzalutamide versus abiraterone plus prednisolone before chemotherapy for Japanese castration-resistant prostate cancer patients: An investigator-initiated, multicenter, randomized controlled trial.

Author

Izumi, Kouji, primary, Shima, Takashi, additional, Mita, Koji, additional, Kato, Yuki, additional, Kamiyama, Manabu, additional, Inoue, Shogo, additional, Tanaka, Nobumichi, additional, Hoshi, Seiji, additional, Okamura, Takehiko, additional, Yoshio, Yuko, additional, Enokida, Hideki, additional, Chikazawa, Ippei, additional, Kawai, Noriyasu, additional, Hashimoto, Kohei, additional, Fukagai, Takashi, additional, Shigehara, Kazuyoshi, additional, Takahara, Shizuko, additional, Kadono, Yoshifumi, additional, and Mizokami, Atsushi, additional

Published
2022
Full Text
View/download PDF

23. EFFICACY AND SAFETY OF 25 AND 50 μg DESMOPRESSIN ORALLY DISINTEGRATING TABLETS IN NOCTURIA DUE TO NOCTURNAL POLYURIA IN JAPANESE MALE PATIENTS

Author

Hayashi, Keiichiro, primary, Fuji, Kohzo, additional, Omizu, Madoka, additional, Hiramatsu, Aya, additional, Koizumi, Shintaro, additional, Matsubara, Eiji, additional, Saito, Katsuyuki, additional, Ishikawa, Kimiyasu, additional, Sasaki, Haruaki, additional, Fukagai, Takashi, additional, and Ogawa, Yoshio, additional

Published
2021
Full Text
View/download PDF

28. Hormonal therapy

Author

Namiki, Mikio, Ueno, Satoru, Kitagawa, Yasuhide, Konaka, Hiroyuki, Mizokami, Atsushi, Koh, Eitetsu, and Fukagai, Takashi

Published
2007
Full Text
View/download PDF

29. Highly accurate colorectal cancer prediction model based on Raman spectroscopy using patient serum

Author

Ito, Hiroaki, primary, Uragami, Naoyuki, additional, Miyazaki, Tomokazu, additional, Yang, William, additional, Issha, Kenji, additional, Matsuo, Kai, additional, Kimura, Satoshi, additional, Arai, Yuji, additional, Tokunaga, Hiromasa, additional, Okada, Saiko, additional, Kawamura, Machiko, additional, Yokoyama, Noboru, additional, Kushima, Miki, additional, Inoue, Haruhiro, additional, Fukagai, Takashi, additional, and Kamijo, Yumi, additional

Published
2020
Full Text
View/download PDF

31. OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single‐dose treatment from a phase III, randomized, double‐blind, placebo‐controlled trial (interim analysis)

Author

Yokoyama, Osamu, primary, Honda, Masashi, additional, Yamanishi, Tomonori, additional, Sekiguchi, Yuki, additional, Fujii, Kenji, additional, Nakayama, Takashi, additional, Mogi, Takao, additional, Kitta, Takeya, additional, Ohyama, Chikara, additional, Kambe, Koichi, additional, Tanahashi, Yoshikatsu, additional, Sasagawa, Isoji, additional, Ootani, Mikinobu, additional, Nozawa, Eiyu, additional, Saito, Toshihiko, additional, Manabe, Fumio, additional, Suzuki, Yasutomo, additional, Tomoe, Hikaru, additional, Takahashi, Satoru, additional, Kawata, Nozomu, additional, Matsushima, Hisashi, additional, Kawai, Taketo, additional, Kinjo, Manami, additional, Fukagai, Takashi, additional, Takahashi, Atsuko, additional, Nakajima, Fumio, additional, Sasaki, Haruaki, additional, Okuno, Norihiko, additional, Itoi, Toshiyuki, additional, Ishiura, Yoshiyuki, additional, Mizokami, Atsushi, additional, Matsuta, Yosuke, additional, Sawada, Norifumi, additional, Miwa, Kosei, additional, Otsuka, Atsushi, additional, Funahashi, Yasuhito, additional, Yoshida, Masaki, additional, Tobiume, Motoi, additional, Kawauchi, Akihiro, additional, Okuno, Hiroshi, additional, Nakamura, Terukazu, additional, Ninomiya, Noriko, additional, Matsushita, Chie, additional, Takenaka, Atsushi, additional, Watanabe, Takeshi, additional, Watanabe, Toyohiko, additional, Ishito, Noritaka, additional, Yamamoto, Yasuyo, additional, Ikeda, Hiroshi, additional, Seki, Narihito, additional, Kanegae, Shigehiro, additional, Suyama, Kenichi, additional, Sagiyama, Kazuyuki, additional, Tokuda, Noriaki, additional, Sakai, Hideki, additional, Nishimura, Hiroaki, additional, and Kawahara, Motoshi, additional

Published
2020
Full Text
View/download PDF

32. Assessment of Intrapelvic Blood Flow with the Penile Brachial Index Using a Toe Blood Pressure Cuff in Japanese Patients with Lower Urinary Tract Symptoms

Author

Hayashi, Keiichiro, primary, Sasaki, Haruaki, additional, Fuji, Kohzo, additional, Hiramatsu, Aya, additional, Yamagishi, Motoki, additional, Matsumoto, Yuki, additional, Matsubara, Eiji, additional, Saito, Katsuyuki, additional, Ishikawa, Kimiyasu, additional, Fukagai, Takashi, additional, and Ogawa, Yoshio, additional

Published
2020
Full Text
View/download PDF

33. Perineal recurrence of prostate ductal adenocarcinoma after transperineal brachytherapy: a case report and literature review

Author

Fukagai, Takashi, primary, Hirayama, Kidai, additional, Morita, Masashi, additional, Nishimura, Kota, additional, Yamatoya, Jin, additional, Noguchi, Tetsuo, additional, Ogawa, Yu, additional, Igarashi, Atsushi, additional, Morota, Madoka, additional, Kato, Masako, additional, Oshinomi, Kazuhiko, additional, Ogawa, Yoshio, additional, and Tsuzuki, Toyonori, additional

Published
2020
Full Text
View/download PDF

34. Prostate Cancer Working Group Report

Author

Namiki, Mikio, Akaza, Hideyuki, Lee, Sang Eun, Song, Jae-Mann, Umbas, Rainy, Zhou, Liqun, Cheok Lee, Boon, Cheng, Christopher, Chung, Moon Kee, Fukagai, Takashi, Hinotsu, Shiro, and Horie, Shigeo

Published
2010
Full Text
View/download PDF

35. Placement of Space OAR hydrogel spacer for prostate cancer patients treated with iodine‐125 low‐dose‐rate brachytherapy

Author

Morita, Masashi, primary, Fukagai, Takashi, additional, Hirayama, Kidai, additional, Yamatoya, Jin, additional, Noguchi, Tetsuo, additional, Ogawa, Yu, additional, Igarashi, Atsushi, additional, Niiya, Akifumi, additional, Kato, Masako, additional, Morota, Madoka, additional, Oshinomi, Kazuhiko, additional, Ogawa, Yoshio, additional, and Lederer, John L, additional

Published
2019
Full Text
View/download PDF

46. 日本人男性におけるα1-Blocker抵抗性のLUTS/BPHに対してTadalafil追加投与の有効性の検討

Author

Hayashi, Keiichiro, Fukagai, Takashi, Sasaki, Haruaki, Morita, Masashi, Igarashi, Atsushi, and Koshikiya, Atsushi

Subjects
LUTS, BPH, 494.9, urologic and male genital diseases, taladafil
Abstract

Alpha 1-blockers are widely used at present for lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH). However, some patients experience little improvement of symptoms, and it is difficult to provide additional treatment. We have additionally administered tadalafil to patients with inadequate symptom improvement, despite treatment with alpha-1 blockers. The subjects were 57 patients with a diagnosis of LUTS/BPH who showed a poor response to treatment with alpha-1 blockers for 1 month or more (international prostate symptom score [IPSS] ≥8 and/or quality of life [QOL] index ≥3). Tadalafil 5 mg was administered on consecutive days to patients orally receiving alpha-1 blockers. We determined IPSS, the QOL index, overactive bladder symptom scores (OABSS), maximum urine flow, residual urine volume, and the sexual health inventory for men (SHIM) before, and 4, 8, and 12 weeks after administration, and then evaluated improvement effects. IPSS, the QOL index, OABSS, and SHIM showed significant improvement (P ＜0.05) at 4 weeks after the start of treatment and onward. IPSS and the QOL index showed greater improvement effects at 8 and 12 weeks. Residual urinary volume was significantly improved only at 8 weeks. However, the maximum urine flow showed no improvement at any time point. Our results demonstrated the additional administration of tadalafil to patients with LUTS showing poor responses to alpha-1 blockers to improve LUTS/BPH symptoms as well as sexual function.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results